Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties.

Lab on a chip·2016
Same author

Functional Immune Anatomy of the Liver-As an Allograft.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during Klebsiella pneumoniae infection.

Mucosal immunology·2014
Same author

Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system.

British journal of cancer·2014
Same author

Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury.

Mucosal immunology·2013
Same author

Hepatic B cells are readily activated by Toll-like receptor-4 ligation and secrete less interleukin-10 than lymphoid tissue B cells.

Clinical and experimental immunology·2013

Related Experiment Video

Updated: Jul 17, 2026

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery
08:09

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery

Published on: August 6, 2019

Bifunctional compounds for targeted hepatic gene delivery.

K S Kim1, Y Lei, D B Stolz

  • 1Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Gene Therapy
|February 9, 2007
PubMed
Summary

Researchers developed novel synthetic gene carriers using galactosyl residues and dendrimers. These compounds effectively deliver DNA to liver cells, showing promise for gene therapy applications.

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Related Experiment Videos

Last Updated: Jul 17, 2026

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery
08:09

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery

Published on: August 6, 2019

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Area of Science:

  • Biomaterials science
  • Gene therapy
  • Nanotechnology

Background:

  • Hepatocyte targeting is crucial for effective liver gene delivery.
  • Developing efficient and safe synthetic gene carriers remains a challenge.
  • Dendrimers offer potential as DNA-binding domains for gene delivery vehicles.

Purpose of the Study:

  • To synthesize bifunctional compounds for targeted gene delivery to hepatocytes.
  • To evaluate the in vitro and in vivo transfection activity of these novel compounds.
  • To optimize the structure of the synthetic gene carriers for enhanced liver cell targeting.

Main Methods:

  • Synthesis of bifunctional compounds featuring galactosyl residues and dendrimer cores.
  • Self-assembly of compounds with plasmid DNA into nanoparticles.
  • In vitro and in vivo transfection assays in liver cells.
  • Structure-activity relationship studies to identify optimal compound design.

Main Results:

  • Synthesized compounds self-assembled with DNA into highly active transfection particles.
  • Optimal transfection activity in liver cells was achieved with compounds bearing three galactosyl residues and 16 dendrimer arms.
  • Demonstrated high transfection efficiency both in vitro and in vivo.
  • Identified a structure-activity relationship for enhanced hepatocyte targeting.

Conclusions:

  • Domain-based design is a successful strategy for creating next-generation synthetic gene carriers.
  • The developed galactosyl-dendrimer conjugates show significant potential for liver-targeted gene therapy.
  • Further development of these synthetic gene carriers could advance gene delivery technologies.